InsiderClue
← All stocks

Xenon Pharmaceuticals Inc.

XENE Net selling
CIK 0001582313 #1255 in the set updated 17 Sep 2026
Bought (120 mo)
$2.62M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$53.66M
$3.26M on a plan · $38.28M straight out of an exercise
Sold at will
$12.11M
33 of 111 sales
Net
−$51.05M
−$9.50M against sales at will

By person

23 insiders · 217 transactions
2.6×

Ian Mortimer holds only 2.6 times base salary in stock. $2.09M of shares against $786.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Ian Mortimer last reported holding, valued at $60.98, the price Common Shares was last bought or sold at on the open market here, on 28 Aug 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
MORTIMER IAN
PRESIDENT & CEO
$43.23K (2)
$24.82M (25) scheduled
−$24.78M
34,223
0.0353%
$2.09M
+545.7%
PIMSTONE SIMON N.
Director
$17.40K (1)
$14.96M (34)
−$14.95M
6,000
0.0062%
$365.86K
−97.2%
EMPFIELD JAMES R.
EVP, Drug Discovery
$24.82K (1)
$3.78M (5) scheduled
−$3.75M
10,000
0.0103%
$609.77K
—
ROBIN SHERRINGTON
EVP, Strategy & Innovation
—
$3.61M (11) scheduled
−$3.61M
8,398
0.0087%
$512.08K
+108.8%
BVF PARTNERS L P/IL entity
10% owner
$2.05M (28)
—
+$2.05M
59,464
0.0614%
$3.63M
−96.9%
AULIN SHERRY
Chief Financial Officer
—
$1.38M (3) scheduled
−$1.38M
0
0.0000%
$0.00
—
GANNON STEVEN
Director
$42.27K (1)
$1.24M (6)
−$1.20M
1,870
0.0019%
$114.03K
—
PATOU GARY
Director
$35.84K (2)
$1.17M (9) scheduled
−$1.13M
29,798
0.0308%
$1.82M
+647.6%
Svoronos Dawn
Director
$140.77K (1)
$967.50K (1)
−$826.73K
31,373
0.0324%
$1.91M
—
KENNEY CHRISTOPHER JOHN
Chief Medical Officer
$20.17K (1)
$694.76K (5) scheduled
−$674.60K
2
<0.0001%
$121.95
+100.0%
HOLLER FRANK A
Director
—
$649.32K (7)
−$649.32K
143,653
0.1483%
$8.76M
−1.5%
DiFabio Andrea
Chief Legal Officer
—
$230.81K (2) scheduled
−$230.81K
7,301
0.0075%
$445.19K
—
Von Seggern Christopher
Chief Commercial Officer
$97.60K (1)
—
+$97.60K
4,000
0.0041%
$243.91K
—
GAROFALO ELIZABETH A.
Director
—
$95.58K (1) scheduled
−$95.58K
2,645
0.0027%
$161.28K
—
AZAB MOHAMMAD
Director
$81.14K (5)
$214.18 (1)
+$80.93K
74,225
0.0766%
$4.53M
+1,403%
Cannon Gillian
Director
—
$63.24K (1) scheduled
−$63.24K
1,455
0.0015%
$88.72K
—
Hayden Michael R
Director
$41.25K (1)
—
+$41.25K
208,282
0.2151%
$12.70M
+169.4%
SCHELLER RICHARD H
Director
$19.95K (1)
—
+$19.95K
7,000
0.0072%
$426.84K
—
WINQUIST RAYMOND
Head, Translational Research
$3.00K (1)
—
+$3.00K
1,000
0.0010%
$60.98K
—
TARNOW MICHAEL M
Director
—
—
—
77,942
0.0805%
$4.75M
+41.3%
COHEN CHARLES J.
VP, Biology
—
—
—
6,550
0.0068%
$399.40K
—
Machado Patrick
Director
—
—
—
2,645
0.0027%
$161.28K
—
Gover Justin D.
Director
—
—
—
2,645
0.0027%
$161.28K
—

Individual transactions

64
Insider
Date
Role
Action
Shares
Price
Amount
MORTIMER IAN
9 Mar 2026
PRESIDENT & CEO
Sold after exercise
65,000
$62.06
$4.03M
MORTIMER IAN
9 Mar 2026
PRESIDENT & CEO
Sold after exercise
61,652
$60.08
$3.70M
MORTIMER IAN
9 Mar 2026
PRESIDENT & CEO
Sold after exercise
43,348
$59.26
$2.57M
MORTIMER IAN
9 Mar 2026
PRESIDENT & CEO
Sold after exercise
2,449
$61.26
$150.03K
MORTIMER IAN
9 Mar 2026
PRESIDENT & CEO
Sold after exercise
10,072
$60.47
$609.05K
MORTIMER IAN
9 Mar 2026
PRESIDENT & CEO
Sold after exercise
12,479
$59.50
$742.50K
MORTIMER IAN
9 Mar 2026
PRESIDENT & CEO
Sold after exercise
21,515
$60.49
$1.30M
MORTIMER IAN
9 Mar 2026
PRESIDENT & CEO
Sold after exercise
31,694
$59.88
$1.90M
MORTIMER IAN
9 Mar 2026
PRESIDENT & CEO
Sold after exercise
21,791
$58.81
$1.28M
MORTIMER IAN
2 Jan 2026
PRESIDENT & CEO
Sold after exercise
2,062
$44.93
$92.65K
MORTIMER IAN
2 Jan 2026
PRESIDENT & CEO
Sold after exercise
37,938
$44.40
$1.68M
MORTIMER IAN
1 Oct 2025
PRESIDENT, CEO & INTERIM CFO
Sold after exercise
25,000
$40.16
$1.00M
MORTIMER IAN
27 Jan 2025
PRESIDENT & CEO
Sold after exercise
1,149
$41.07
$47.19K
MORTIMER IAN
27 Jan 2025
PRESIDENT & CEO
Sold after exercise
15,166
$40.46
$613.62K
MORTIMER IAN
24 Jan 2025
PRESIDENT & CEO
Sold after exercise
22,468
$40.20
$903.21K
MORTIMER IAN
23 Jan 2025
PRESIDENT & CEO
Sold after exercise
16,217
$40.08
$649.98K
AULIN SHERRY
18 Dec 2024
Chief Financial Officer
Sold after exercise
11,510
$41.19
$474.10K
AULIN SHERRY
18 Dec 2024
Chief Financial Officer
Sold after exercise
7,199
$41.23
$296.81K
PATOU GARY
22 Nov 2024
Director
Sold after exercise
2,040
$41.05
$83.74K
PATOU GARY
22 Nov 2024
Director
Sold after exercise
2,851
$41.11
$117.20K
GAROFALO ELIZABETH A.
8 Mar 2024
Director
Sold after exercise
2,092
$45.69
$95.58K
ROBIN SHERRINGTON
7 Mar 2024
EVP, Strategy & Innovation
Sold after exercise
6,118
$46.30
$283.26K
ROBIN SHERRINGTON
7 Mar 2024
EVP, Strategy & Innovation
Sold after exercise
1,019
$46.15
$47.03K
PATOU GARY
13 Dec 2023
Director
Sold after exercise indirect
7,598
$41.05
$311.90K
PATOU GARY
13 Dec 2023
Director
Sold after exercise
3,977
$39.84
$158.44K
PATOU GARY
13 Dec 2023
Director
Sold after exercise
2,303
$39.10
$90.05K
PATOU GARY
13 Dec 2023
Director
Sold after exercise
5,100
$38.94
$198.59K
PIMSTONE SIMON N.
1 Jun 2023
Director
Sold after exercise
24,255
$38.78
$940.61K
PIMSTONE SIMON N.
1 Jun 2023
Director
Sold after exercise
7,458
$38.97
$290.64K
PIMSTONE SIMON N.
31 May 2023
Director
Sold after exercise
26,856
$38.69
$1.04M
PIMSTONE SIMON N.
31 May 2023
Director
Sold after exercise
23,670
$38.81
$918.63K
PIMSTONE SIMON N.
31 May 2023
Director
Sold after exercise
12,000
$38.53
$462.36K
MORTIMER IAN
24 May 2023
PRESIDENT & CEO
Sold after exercise
1,407
$41.49
$58.38K
MORTIMER IAN
24 May 2023
PRESIDENT & CEO
Sold after exercise
13,179
$41.37
$545.22K
MORTIMER IAN
24 May 2023
PRESIDENT & CEO
Sold after exercise
17,069
$41.44
$707.34K
PIMSTONE SIMON N.
7 Mar 2023
Director
Sold after exercise
8,242
$36.94
$304.46K
PIMSTONE SIMON N.
7 Mar 2023
Director
Sold after exercise
10,990
$37.01
$406.74K
PATOU GARY
25 Nov 2022
Director
Sold after exercise
1,937
$34.79
$67.39K
AULIN SHERRY
2 Sep 2022
Chief Financial Officer
Sold after exercise
15,355
$39.57
$607.60K
ROBIN SHERRINGTON
1 Sep 2022
EVP, Strategy & Innovation
Sold after exercise
8,776
$38.80
$340.51K
ROBIN SHERRINGTON
1 Sep 2022
EVP, Strategy & Innovation
Sold after exercise
35,103
$38.03
$1.33M
ROBIN SHERRINGTON
31 Aug 2022
EVP, Strategy & Innovation
Sold after exercise
21,352
$38.57
$823.55K
EMPFIELD JAMES R.
12 Aug 2022
EVP, Drug Discovery
Sold after exercise
21,875
$38.68
$846.13K
EMPFIELD JAMES R.
12 Aug 2022
EVP, Drug Discovery
Sold after exercise
35,868
$38.08
$1.37M
EMPFIELD JAMES R.
7 Mar 2022
EVP, Drug Discovery
Sold after exercise
31,048
$30.54
$948.21K
EMPFIELD JAMES R.
7 Mar 2022
EVP, Drug Discovery
Sold after exercise
1,805
$30.62
$55.27K
PIMSTONE SIMON N.
7 Mar 2022
Director
Sold after exercise
2,500
$30.55
$76.38K
PIMSTONE SIMON N.
7 Mar 2022
Director
Sold after exercise
7,500
$30.50
$228.75K
PIMSTONE SIMON N.
7 Mar 2022
Director
Sold after exercise
2,500
$30.52
$76.30K
PIMSTONE SIMON N.
7 Mar 2022
Director
Sold after exercise
4,516
$30.44
$137.47K
PIMSTONE SIMON N.
7 Mar 2022
Director
Sold after exercise
4,516
$30.45
$137.51K
PIMSTONE SIMON N.
7 Mar 2022
Director
Sold after exercise
4,517
$30.49
$137.72K
PIMSTONE SIMON N.
7 Mar 2022
Director
Sold after exercise
5,037
$30.60
$154.13K
EMPFIELD JAMES R.
4 Mar 2022
EVP, Drug Discovery
Sold after exercise
18,315
$30.79
$563.92K
ROBIN SHERRINGTON
4 Mar 2022
EVP, Strategy & Innovation
Sold after exercise
5,000
$30.23
$151.15K
ROBIN SHERRINGTON
4 Mar 2022
EVP, Strategy & Innovation
Sold after exercise
5,000
$31.05
$155.25K
ROBIN SHERRINGTON
4 Mar 2022
EVP, Strategy & Innovation
Sold after exercise
5,000
$30.15
$150.75K
ROBIN SHERRINGTON
4 Mar 2022
EVP, Strategy & Innovation
Sold after exercise
6,710
$30.56
$205.06K
PIMSTONE SIMON N.
4 Mar 2022
Director
Sold after exercise
4,793
$30.56
$146.47K
PIMSTONE SIMON N.
4 Mar 2022
Director
Sold after exercise
4,532
$30.66
$138.95K
ROBIN SHERRINGTON
28 May 2021
EVP, Strategy & Innovation
Sold after exercise
2,912
$18.81
$54.77K
ROBIN SHERRINGTON
28 May 2021
EVP, Strategy & Innovation
Sold after exercise
3,155
$18.81
$59.35K
HOLLER FRANK A
27 May 2021
Director
Sold after exercise
8,485
$18.68
$158.50K
HOLLER FRANK A
27 May 2021
Director
Sold after exercise
2,579
$18.69
$48.20K
Show all 217 transactions →

What was left out

Form 4 filings counted 256
Amendments (4/A) skipped 3
Filings about a different issuer 0
Unreadable filings 0
Joint filings 6
Sales on a Rule 10b5-1 plan 14
Sales straight out of an exercise 64
Sales at will 33
Transactions with no price 0
Shares from compensation/vesting 4,418,692
Sales filed before the plan box existed 23
History held since 27 Sep 2016